MCID: PRT056
MIFTS: 12

Protein R Deficiency

Categories: Rare diseases

Aliases & Classifications for Protein R Deficiency

MalaCards integrated aliases for Protein R Deficiency:

Name: Protein R Deficiency 50

Classifications:



Summaries for Protein R Deficiency

MalaCards based summary : Protein R Deficiency The drugs Iron and Emtricitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, eye and t cells.

Related Diseases for Protein R Deficiency

Symptoms & Phenotypes for Protein R Deficiency

Drugs & Therapeutics for Protein R Deficiency

Drugs for Protein R Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
2
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
3
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
4
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
5
Amprenavir Approved Phase 4,Phase 2 161814-49-9 65016
6
Didanosine Approved Phase 4 69655-05-6 50599
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
9
Indinavir Approved Phase 4 150378-17-9 5362440
10
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
11
Nelfinavir Approved Phase 4 159989-64-7 64143
12
Nevirapine Approved Phase 4 129618-40-2 4463
13
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
14
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
15
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
16
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027
17
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
18
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
19
Lopinavir Approved Phase 4,Phase 3 192725-17-0 92727
20
Citalopram Approved Phase 4 59729-33-8 2771
21
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
23 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
25 Imatinib Mesylate Phase 4 123596
26 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Ferric Compounds Phase 4
29 ferric gluconate Phase 4
30 Ferric oxide, saccharated Phase 4
31 Hematinics Phase 4,Phase 2
32 Micronutrients Phase 4,Phase 1
33 Trace Elements Phase 4,Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
35 Antibodies Phase 4,Phase 3,Phase 2,Early Phase 1
36 Anti-HIV Agents Phase 4,Phase 3,Phase 2
37 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
39 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
40 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
41 Hepatitis C Antibodies Phase 4
42 HIV Integrase Inhibitors Phase 4,Phase 3
43 Immunoglobulins Phase 4,Phase 3,Phase 2,Early Phase 1
44 Integrase Inhibitors Phase 4,Phase 3
45 Interferon-alpha Phase 4
46 interferons Phase 4,Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
48 Raltegravir Potassium Phase 4,Phase 3
49 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2
50
Tenofovir Phase 4,Phase 3 147127-20-6 464205

Interventional clinical trials:

(show top 50) (show all 117)

id Name Status NCT ID Phase Drugs
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
2 Effect of Two Iron Preparations on Protein in the Urine Completed NCT00354692 Phase 4 Sodium Ferric Gluconate and Iron sucrose
3 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
4 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
5 Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds Completed NCT01285050 Phase 4 Antiretroviral therapy (ART);raltegravir;Emtricitabine and tenofovir disoproxil fumarate
6 HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) Completed NCT00192660 Phase 4 Lamivudine;Stavudine;Didanosine;Zidovudine;Tenofovir;Abacavir;Efavirenz (EFV);Nevirapine;Indinavir;Saquinavir;Amprenavir;Ritonavir;Nelfinavir;Tipranavir;enfuvirtide (T20)
7 Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers Completed NCT00050180 Phase 4 Midazolam;Indinavir;Saquinavir
8 Study of the Effects of Fabrazyme Treatment on Lactation and Infants Recruiting NCT00230607 Phase 4 agalsidase beta
9 Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients Recruiting NCT00555555 Phase 4
10 Escitalopram Effects on CSF Amyloid Beta Active, not recruiting NCT02161458 Phase 4 Escitalopram 20mg for 2 weeks;Escitalopram 20mg for 8 weeks;Escitalopram 30mg for 8 weeks;Placebo
11 IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children Active, not recruiting NCT01818258 Phase 4 ZDV+3TC+LPV/r
12 Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults Terminated NCT01791465 Phase 4 extended-release exenatide
13 Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
14 Efficacy and Mechanisms of GLN Dipeptide in the SICU Completed NCT00248638 Phase 3 Glutamine dipeptide with 15% Clinisol;15% Clinisol
15 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks Completed NCT00168103 Phase 2, Phase 3
16 A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease Completed NCT00074971 Phase 3 Fabrazyme (agalsidase beta)
17 Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome Completed NCT01077960 Phase 3
18 A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency Completed NCT00885742 Phase 3
19 An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency Completed NCT00945906 Phase 3
20 Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) Completed NCT00711009 Phase 3 lopinavir/ritonavir (LPV/r);emtricitabine/tenofovir disoproxil fumarate (FTC/TDF);raltegravir (RAL)
21 Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients Completed NCT00561093 Phase 3 pentoxiphylline;Placebo pill imitating pentoxiphylline
22 A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Completed NCT02105987 Phase 3 ABC/DTG/3TC FDC;Ongoing cART regimen
23 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency Recruiting NCT03113760 Phase 3 Tadekinig alfa;Placebo
24 Apotransferrin in Atransferrinemia Recruiting NCT01797055 Phase 2, Phase 3 Human apotransferrin
25 Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study Terminated NCT01237340 Phase 3 Saizen®
26 Fibrinogen Concentrate (Human) − Efficacy and Safety Study Withdrawn NCT00916656 Phase 3
27 Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients Unknown status NCT01394835 Phase 2 Alpha -1 Antitrypsin;Alpha-1 Antitrypsin;AAT
28 Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Completed NCT01054339 Phase 2 rAAV1-CB-hAAT
29 Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS) Completed NCT01473264 Phase 1, Phase 2 recombinant human CC10 (rhCC10);recombinant human CC10 (rhCC10);placebo
30 IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency Completed NCT00228852 Phase 1, Phase 2 Busulfan, Fludarabine and ATG
31 Treatment of Calcium Deficiency in Young Women Completed NCT00000426 Phase 2 Calcium supplement
32 N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Completed NCT01265563 Phase 2 N-acetylcysteine placebo and silibin placebo;N-acetylcysteine active and silibin placebo;N-acetylcysteine placebo and silibin active;N-acetylcysteine active and silibin active;N-acetylcysteine active + high-dose silibin active
33 HORMA: Hormonal Regulators of Muscle and Metabolism in Aging Completed NCT00183040 Phase 2 Topical testosterone;Recombinant human growth hormone
34 A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease Completed NCT00269945 Phase 2 epoetin alfa
35 A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy Completed NCT00270283 Phase 2 epoetin alfa
36 A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy Completed NCT00270270 Phase 2 epoetin alfa
37 A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease Completed NCT00270010 Phase 2 epoetin alfa
38 A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency Completed NCT00883090 Phase 2
39 Human Fibrinogen - Pharmacokinetics Completed NCT00496262 Phase 2
40 A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss Completed NCT00000925 Phase 2 Optimune oral nutritional supplement
41 A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients Completed NCT00001085 Phase 2 Amprenavir;Lamivudine;Zidovudine
42 Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency Recruiting NCT01379469 Phase 2 Drug-Carbamazepine (Tegretol XR);Carbamazepine (Tegretol XR) Placebo
43 NF1 Health Sciences Protocol Recruiting NCT02964884 Phase 2 Lovastatin 20 MG;Placebo Oral Tablet;Lovastatin 40 MG
44 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Recruiting NCT02859441 Phase 1, Phase 2 Ranibizumab;E10030
45 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Recruiting NCT02465060 Phase 2 Afatinib;Akt inhibitor AZD5363;Binimetinib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib;WEE1 Inhibitor AZD1775
46 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency Recruiting NCT02199496 Phase 1, Phase 2
47 A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency Active, not recruiting NCT02476916 Phase 2 AG-348
48 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors Active, not recruiting NCT02015065 Phase 2 Vandetanib
49 ALS Reversals - Lunasin Regimen Active, not recruiting NCT02709330 Phase 2 Lunasin Regimen
50 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Enrolling by invitation NCT02676843 Phase 2 18F-AV-1451

Search NIH Clinical Center for Protein R Deficiency

Genetic Tests for Protein R Deficiency

Anatomical Context for Protein R Deficiency

MalaCards organs/tissues related to Protein R Deficiency:

39
Liver, Eye, T Cells, Testes, Lung, Bone, Colon

Publications for Protein R Deficiency

Variations for Protein R Deficiency

Expression for Protein R Deficiency

Search GEO for disease gene expression data for Protein R Deficiency.

Pathways for Protein R Deficiency

GO Terms for Protein R Deficiency

Sources for Protein R Deficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....